[go: up one dir, main page]

WO2008035757A1 - Aliment de type gelée contenant de l'ubiquinol - Google Patents

Aliment de type gelée contenant de l'ubiquinol Download PDF

Info

Publication number
WO2008035757A1
WO2008035757A1 PCT/JP2007/068350 JP2007068350W WO2008035757A1 WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1 JP 2007068350 W JP2007068350 W JP 2007068350W WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquinol
jelly
food
ubiquinone
oil
Prior art date
Application number
PCT/JP2007/068350
Other languages
English (en)
Japanese (ja)
Inventor
Hideyuki Kishida
Taizo Kawabe
Kazunori Hosoe
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to JP2008535395A priority Critical patent/JPWO2008035757A1/ja
Publication of WO2008035757A1 publication Critical patent/WO2008035757A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a jelly food containing ubiquinol, which can be easily replenished with ubiquinol essential to a living body by ingesting it in the same way as normal food in daily life, and its use. It is.
  • Ubiquinol is a 2-electron reductant of ubiquinone, a benzoquinone derivative widely distributed in the living world.
  • Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of the electron transport system. It is an indispensable substance for maintaining the functions of living bodies.
  • Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
  • ubiquinol and ubiquinone In vivo, ubiquinol and ubiquinone have a certain equilibrium relationship, and ubiquinol / ubiquinone absorbed in the living body is known to be mutually oxidized / reduced. Normally, it is said that 60 to 90% of the total weight of ubiquinol and ubiquinone is present as ubiquinol in the living body! /.
  • the ubiquinone content in human heart is reported to be 11.0 g / g between the ages of 19 and 21, compared with 47.2 g / g between ages 77 and 81.
  • Non-Patent Document 1 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
  • Non-patent Document 4 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
  • the ubiquinone content of the LDL cholesterol fraction is reduced (Non-patent document 4).
  • ubiquinone has an effect of improving or preventing heart disease, hypertension, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological disease, allergy, fertility, motor ability, immune function, fatigue, etc. Expected.
  • Non-patent document 6 ubiquinone administration has been reported to increase cardiac function
  • ubiquinone has an effect to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction
  • Non-patent document 7 Non-patent document 8
  • arteriosclerosis hypertension
  • diabetes cancer
  • periodontal disease allergy, etc.
  • Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12 Fertility It is known to have an improving effect, an inhibition of LDL cholesterol oxidation, an effect of reducing the number of dialysis in renal dialysis patients, and an effect of enhancing nonspecific immunity (Non-patent Document 13, Non-Patent Document 14).
  • Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
  • ubiquinol In addition to taking ubiquinol in this way, its strength is expected to be useful. In order to increase the absorption, ubiquinol as such is dissolved in oils and fats, and in some cases, surfactants are also added, and it is generally taken as a capsule to prevent oxidation. Is. However, in the case of capsules, they are difficult to take for people with low swallowing ability, such as the elderly and the sick!
  • ubiquinol-enriched oil-and-fat-containing foods have been reported as foods containing ubiquinol S, in order to include ubiquinol, a fat-soluble substance, in foods.
  • Ubiquinol is dissolved or coexisting in fats and oils.
  • Patent Document 1 JP-A-10-109933
  • Patent Document 2 JP-A-10-330251
  • Patent Document 3 WO03 / 061395
  • Non-Patent Document 1 Lipids, 24, 579-584 (1989)
  • Non-Patent Document 2 N mark hron, 66, 153-156 (1994)
  • Non-Patent Document 3 BioFactors, 1, 303-306 (1988)
  • Non-Patent Document 4 Atherosclerosis, 129, 119-126 (1997)
  • Non-Patent Document 5 Clinical Investigator, 71, S97-S102 (1993)
  • Non-Patent Document 6 Clinical Investigator, 71, S71-S75 (1993)
  • Non-Patent Document 7 Inter. J. Cardiology, 68, 23-29 (1999)
  • Non-Patent Document 8 Cardiovasc. Drugs Ther., 12, 347-353 (1998)
  • Non-Patent Document 9 Atherosclerosis, 148, 275-282 (1999)
  • Non-Patent Document 10 Curr. Therap. Res., 51, 668-672 (1992)
  • Non-Patent Document 11 Journal of Oral Hygiene, 43, 667-672 (1993)
  • Non-Patent Document 12 Clinical and Research, 58, 1349-1352 (1981)
  • Non-Patent Document 13 Mol. Aspects Med., 18, S85-S103 (1997)
  • Non-Patent Document 14 ⁇ 1 Aspects Med., 15, S213-S219 (1994)
  • Non-Patent Document 15 Acta Diabetol., 42, 179-181 (2005)
  • the purpose of the present invention is to obtain ubiquinol, which is apt to be reduced or insufficient, in healthy people, even though it is indispensable for the living body by ingesting it in the same way as normal food in daily life. It can be replenished easily and efficiently even for people with lower swallowing ability, such as older people and sick people, and it is a problem in modern people's eating habits! ⁇ ⁇ To provide jelly-like foods and their uses.
  • the present inventors use a gelling agent in place of fats and oils to make a jelly form, whereby ubiquinol can be stably and uniformly dispersed and a jelly-like food with excellent absorbability can be obtained. I found out for the first time. Such jelly-like foods are swallowing ability such as elderly and sick It is also useful for people who have fallen. That is, the present invention is as follows.
  • One or more gels selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan as a gelling agent [1] or [2] jelly, characterized by using an agent
  • Viscosity is 5.0 X 10 2 —1.0 X 10 5 mPa 's and / or hardness is 5 X 10 4 N / m 2 or less [1] to [3] Food.
  • the jelly-like food of the present invention can be consumed in the same way as normal food in daily life.
  • it is also a problem in the dietary habits of modern people who can easily and efficiently replenish even those with reduced swallowing ability such as elderly people and sick people! / Low calorie favorable for excessive energy Food.
  • the jelly-like food of the present invention is characterized by containing ubiquinol.
  • the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol.
  • the ratio is not particularly limited, but it is preferable that the content of ubiquinol is high! /, So that the weight ratio of ubiquinol / ubiquinone. 40/60 or more is preferred 60/40 or more is more preferred 80/20 is more preferred 95/5 is more preferred 99/1 is most preferred.
  • the ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method. However, if careful consideration is given to safety for living organisms, it can be used for foods such as meat and fish.
  • “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, the (aU-E) -isomer of the (aU-E) -isomer obtained by the fermentation method. It does not prevent the conversion of ubiquinone and / or ubiquinol into a desired ratio of ubiquinol by treatments such as oxidation and reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
  • ubiquinol used in the present invention is produced by using ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, using sodium borohydride, sodium dithionite (hydrosulfite). This can be done by reducing by a conventional method using common reducing agents such as sodium) and zinc. After the reduction, crystallization may be concentrated by chromatography. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
  • the ratio of ubiquinone and ubiquinol is usually determined by quantifying the amount of ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculating the ratio of the amounts. Using a system incorporating a mechanical detector, the ratio of ubiquinone and ubiquinol can be determined from the peak area. In systems incorporating electrochemical detectors, redox substances can be specifically measured and the sensitivity is high! Therefore, when measuring the proportion of ubiquinol present in a sample in a very small amount, Highly useful. Specifically, it can be measured under the following HPLC conditions by incorporating an electrochemical detector manufactured by Shiseido Co., Ltd. into an Shimadzu HPLC analyzer.
  • the jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form.
  • the jelly-like food is a jelly or a jelly-based food by a gelling agent such as gelatin, agar, or konjac. , Tapio power, warabimochi, litter, jam, boiled rice. Further, these gel-like compositions may have solids.
  • the material used for the jelly-like food of the present invention is not particularly limited as long as it has an appropriate viscosity added to a gel food raw material or a liquid food raw material.
  • the jelly-like food of the present invention is produced by using a gelling agent that is acceptable as a food and, if necessary, heat treatment or addition of water to form a gel or so-called jelly. Touch with force S.
  • the gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, potato starch (warabiko), tapio force starch, and other starches, agar , Gelatin, konjac flour (Darkmananan, galatatomannan), pectin, carrageenan, alginic acid and its salts, sirium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, cara gum, tragacanth gum, gati gum, Xanthan gum, dielan gum (native dielan gum, deacyl type dielan gum), tara gum, arabinogalatatan, fur celerin, manolemero, curdlan, punoreran, dextran, canolepoxy methylenoresenorelona And cellulose derivatives such as Li ⁇ -time, and the like.
  • Starches agar, gelatin, konjac flour, and pectin are preferable. More preferred are agar, gelatin, konjac flour, pectin, kataguri starch, katsu starch, bran starch, tapio force starch. Two or more of these gelling agents do not work.
  • the jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to an elastic semi-solid, so-called jelly or jelly-like beverage. It is preferable to have a viscosity of 5.0 ⁇ 10 2 mPa ′s or more under the temperature condition at the time of ingestion, and the upper limit thereof is preferably 1.0 ⁇ 10 5 mPa ′s or less.
  • the hardness is more preferably 5 ⁇ 10 4 N / m 2 or less, which is preferably 6 ⁇ 10 4 N / m 2 or less.
  • viscosity means “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity is the property that resists the force of squeezing when friction is applied to the inside when it is applied.
  • Hardness here refers to "resistance when compressed at a constant speed”. When a local force (concentrated load) is applied to a substance from outside in a short time, the degree of deformation of the substance indicated at that time is shown. The strength of the resistance against the resultant deformation is determined as hardness. [0030] The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
  • the jelly-like food according to the present invention can be used as a food for dysphagia and as a dietary supplement.
  • the number of elderly people with movement disorders such as bedridden 'severe dementia' and sequelae of stroke is increasing. If the swallowing function is impaired, food and beverages cannot be swallowed normally, and aspiration that is accidentally drawn into the trachea can lead to death of asphyxia and aspiration pneumonia! is there.
  • a liquid with a low viscosity like water is most easily swallowed by healthy people, but it is known that a person who has difficulty swallowing is less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important, and if it is not soft enough, it will be difficult to knead and mix.
  • the method for adjusting to the target viscosity and hardness is not particularly limited, and the type and amount of the gelling agent are adjusted, and other thickeners are used as appropriate.
  • a known method can be used.
  • gelatin and agar or carrageenan are used as a gelling agent, or carrageenan and xanthan gum are used.
  • the method includes using native dielan gum in combination.
  • An antioxidant, an organic acid, and vitamins may be added to the jelly-like food of the present invention.
  • Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, dartathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD) Glutathione peroxidase, dartathione S transferase, dartathione reductase, force tarase, ascorbate peroxidase, and mixtures thereof.
  • SOD superoxide dismutase
  • This antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol to oxidation and obtaining a more stable and high effect.
  • the organic acid is not particularly limited, but examples thereof include succinic acid, succinic acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, Examples include propionic acid, butyric acid, valeric acid, isochenoic acid, and mixtures thereof.
  • Organic acids are preferred in that they can add an appropriate flavor to the jelly-like food of the present invention, which is not only a component useful for the body itself.
  • the vitamins are not particularly limited.
  • vitamin A vitamin B (vitamin Bl, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamins, vitamins , Biotin, pantothenic acid, nicotinic acid, and mixtures thereof.
  • the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbentiamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, otato thiamine, All of the compounds having physiological activity as vitamin B1, such as prosultiamine, can be included.
  • antioxidants organic acids, and vitamins may be used in combination of two or more.
  • ingredients contained in the jelly-like food of the present invention are not particularly limited as long as they are ingredients that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, flavors, antiseptics Agents, colorants, preservatives, etc. can be used.
  • the saccharide is not particularly limited, and examples thereof include sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, poly And water-soluble saccharides such as dextrose, and mixtures thereof.
  • the sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
  • the fruit juice is not particularly limited, and examples thereof include apple juice, orange juice, grape juice, melon juice, lemon juice and the like.
  • the flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
  • the fragrance is not particularly limited, and examples thereof include menthol, carvone, vanetol, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3 (1-menthoxy) pronone 1, 2-dionole, and chimole.
  • Linalool Linalool, linalino acetate, limonene, menton, menthyl acetate, N-substituted paramentan 1-carboxamide, vinylene, octanolenodehydride, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate , Allylcyclohexanepropionate, methylanthranilate, ethinoremethinoreethino glycidate, nonylin, undecalactone, hexananol, ethinoreanoreconole, propinoreanoreconole, butanol Single-flavored products such as soaminoleanolecole, hexenol, dimethylsulfide, cycloten, furfural, trimethylvirazone, ethyllatatate, ethylthi
  • the preservative is not particularly limited, and examples thereof include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citrate, sodium citrate, salicylic acid, Sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate , Butyl paraoxybenzoate Propyl parabenzoate, methyl paraoxybenzoate, 1 menthol, eucalyptus oil, and mixtures thereof.
  • the colorant is not particularly limited, and it is possible to use one that is permitted to be added to food, for example, Blue No. 1, Yellow No. 4, Green No. 3, Red No. 5, Lake Examples thereof include dyes, titanium dioxide, red cabbage dyes, red potato dyes, purple potato dyes, gardenia dyes, cochineal dyes, caramel dyes, chlorophylls, and mixtures thereof.
  • the preservative is not particularly limited.
  • benzoic acid sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citrate, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D sorbitol , Sorbic acid, potassium sorbate, sodium dehydroacetate, isoptyl noroxybenzoate, isopropyl noroxybenzoate, ethyl parabenzoate, butyl parabenzoate, propyl parabenzoate, methyl paraoxybenzoate, propylene glycol , Phosphoric acid, and mixtures thereof.
  • the jelly-like food of the present invention may contain a slight amount of fat and oil components.
  • the amount of fat used is preferably 10% by weight or less, and preferably 5% by weight or less, based on the total amount of food. More preferably, it is 1% by weight or less, more preferably less than 0.5% by weight.
  • ubiquinol can be suitably dispersed in the food, so that the content of fat and oil relative to ubiquinol in the food can be, for example, equal or less, and even less than half. Is not included at all!
  • the jelly-like food of the present invention is a general food, as a dietary supplement and a health food, and is low in ubiquinol for not only healthy subjects but also elderly people and sick people with some disease. Can be consumed as a calorie food. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can also be applied to animals such as pets, which have been difficult to consume in the past.
  • a cup or the like In addition to being provided as a jelly loaded in a bag or as a jelly-like beverage filled in a bouch or the like, the user can also prepare a jelly-like powder by cooking such as water and / or heating. Provided as a solid form.
  • the amount of the jelly-like food of the present invention is not particularly limited, but the daily dose for adults is lmg to;! OOOmg, preferably 10mg to 500mg, more preferably 30mg to 300mg. .
  • a lOOOOg ethanol solution, lOOg liquor, quinone (purity 99.4%) and 60 g L-asconolevic acid were added, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C, and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing ubiquinol lOOg), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry.
  • the obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C), and the wet crystals were further dried under reduced pressure (20-40 ° C). C,;! To 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
  • lOOg ubiquinone (purity 99.4%) was dissolved in lOOOg heptane solution at 25 ° C. While stirring, sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added an aqueous solution prepared by adding 1000 ml of water to lOOg, and a reduction reaction was performed at 25 ° C and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with degassed saturated saline lOOOg. As described above, all operations were performed in a nitrogen atmosphere.
  • This heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C (containing lOOg of ubiquinol). 50 g of water was added to the ethanol solution, and while stirring, the solution was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to precipitate crystals. All operations are nitrogen Performed under atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were cooled with cold ethanol and cold water.
  • a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
  • oily components are separated by solid-liquid separation according to a conventional method, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C, and ubiquinol is dispersed in gelatin.
  • a particulate composition (model sample of jelly-like food) was obtained.
  • This composition and the ubiquinol crystals of Production Example 1 were used for rats respectively.
  • An evaluation sample was packed in a capsule.
  • Cmax maximum plasma concentration of ubiquinone
  • AUC area under the time course curve of the concentration of ubiquinone
  • ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, citrate Na, vitamins, and a cup-shaped container with sufficient stirring. The jelly-like food containing ubiquinol was obtained. The taste of the resulting jelly-like food was good.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)

Abstract

La présente invention a trait à un aliment de type gelée contenant de l'ubiquinol. Il a été découvert que l'ubiquinol peut être dispersée de façon stable et homogène en utilisant un gélifiant en tant que produit de remplacement d'une matière grasse ou similaire. De la sorte, il devient possible de fournir facilement et efficacement de l'ubiquinol, qui est essentiellement requise par les corps vivants mais qui montre fréquemment une tendance à diminuer ou à manquer, non seulement pour les personnes normales mais aussi pour les personnes présentant des troubles de la capacité de déglutition telles que les personnes âgées et les personnes malades. En raison de sa faible teneur en matière grasse, l'aliment de type gelée décrit ci-dessus est avantageux pour l'homme moderne qui a tendance à ingurgiter trop d'énergie.
PCT/JP2007/068350 2006-09-22 2007-09-21 Aliment de type gelée contenant de l'ubiquinol WO2008035757A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008535395A JPWO2008035757A1 (ja) 2006-09-22 2007-09-21 ユビキノールを含有するゼリー状食品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-257240 2006-09-22
JP2006257240 2006-09-22

Publications (1)

Publication Number Publication Date
WO2008035757A1 true WO2008035757A1 (fr) 2008-03-27

Family

ID=39200580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/068350 WO2008035757A1 (fr) 2006-09-22 2007-09-21 Aliment de type gelée contenant de l'ubiquinol

Country Status (2)

Country Link
JP (1) JPWO2008035757A1 (fr)
WO (1) WO2008035757A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041449A1 (fr) * 2007-09-25 2009-04-02 Kaneka Corporation Agent anti-obésité
GB2494475A (en) * 2011-09-12 2013-03-13 Works With Water Nutraceuticals Ltd A nutraceutical supplement and method of making
JP2013111064A (ja) * 2011-11-30 2013-06-10 Q P Corp 容器入り大根おろし含有液状調味料
WO2014188861A1 (fr) * 2013-05-20 2014-11-27 ユーハ味覚糖株式会社 Composition de type gel présentant une teneur élevée en ubiquinol
JP2014226050A (ja) * 2013-05-20 2014-12-08 ユーハ味覚糖株式会社 還元型コエンザイムｑ１０含有グミキャンディの製造方法および該製造方法を用いて得られるグミキャンディ
JP2015029452A (ja) * 2013-08-01 2015-02-16 江崎グリコ株式会社 冷凍ゼリー
JP2015104342A (ja) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 ユビキノール高含有ゲル状組成物
JP2015105243A (ja) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 ユビキノール含有液状組成物
JPWO2013132670A1 (ja) * 2012-03-05 2015-07-30 テルモ株式会社 半固形化栄養剤
JP2015209398A (ja) * 2014-04-25 2015-11-24 ユーハ味覚糖株式会社 高吸収型ユビキノール製剤

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01206960A (ja) * 1988-02-16 1989-08-21 Takenori Kato ゲル状物
JPH03224452A (ja) * 1990-01-31 1991-10-03 Kyokuto Internatl Corp 栗様食品
JPH0630714A (ja) * 1992-07-20 1994-02-08 Meiji Seika Kaisha Ltd ゼリー生地の調製方法
JP2002218917A (ja) * 2001-01-23 2002-08-06 Sanei Gen Ffi Inc 不溶性固形物が分散されたゲル組成物及びその応用
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
JP2003504479A (ja) * 1999-07-12 2003-02-04 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 架橋剤を含有しない調製物
WO2003061395A1 (fr) * 2002-01-18 2003-07-31 Kaneka Corporation Aliments contenant des matieres grasses, enrichis en ubiquinol
JP2004173678A (ja) * 2002-09-30 2004-06-24 Morinaga & Co Ltd 低離水性ゲル状組成物及びその製造方法
JP2005143380A (ja) * 2003-11-14 2005-06-09 Domo Corporation:Kk スッポン卵を使用した栄養食品
JP2005143365A (ja) * 2003-11-13 2005-06-09 Toshihiro Nomura 脂溶性有効成分配合食品
WO2005097091A1 (fr) * 2004-04-09 2005-10-20 Kaneka Corporation Composition comprenant le coenzyme q10 et un composé de carotènoïde
JP2005328803A (ja) * 2004-05-21 2005-12-02 Towa Kagaku Kk 活力促進・老化防止食品及びその製造方法
JP2006022064A (ja) * 2004-07-09 2006-01-26 Asahi Kasei Pharma Kk 動脈硬化の予防及び／又は改善剤、機能性食品、又は化粧料
JP2006070016A (ja) * 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01206960A (ja) * 1988-02-16 1989-08-21 Takenori Kato ゲル状物
JPH03224452A (ja) * 1990-01-31 1991-10-03 Kyokuto Internatl Corp 栗様食品
JPH0630714A (ja) * 1992-07-20 1994-02-08 Meiji Seika Kaisha Ltd ゼリー生地の調製方法
JP2003504479A (ja) * 1999-07-12 2003-02-04 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 架橋剤を含有しない調製物
JP2002218917A (ja) * 2001-01-23 2002-08-06 Sanei Gen Ffi Inc 不溶性固形物が分散されたゲル組成物及びその応用
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
WO2003061395A1 (fr) * 2002-01-18 2003-07-31 Kaneka Corporation Aliments contenant des matieres grasses, enrichis en ubiquinol
JP2004173678A (ja) * 2002-09-30 2004-06-24 Morinaga & Co Ltd 低離水性ゲル状組成物及びその製造方法
JP2005143365A (ja) * 2003-11-13 2005-06-09 Toshihiro Nomura 脂溶性有効成分配合食品
JP2005143380A (ja) * 2003-11-14 2005-06-09 Domo Corporation:Kk スッポン卵を使用した栄養食品
WO2005097091A1 (fr) * 2004-04-09 2005-10-20 Kaneka Corporation Composition comprenant le coenzyme q10 et un composé de carotènoïde
JP2005328803A (ja) * 2004-05-21 2005-12-02 Towa Kagaku Kk 活力促進・老化防止食品及びその製造方法
JP2006022064A (ja) * 2004-07-09 2006-01-26 Asahi Kasei Pharma Kk 動脈硬化の予防及び／又は改善剤、機能性食品、又は化粧料
JP2006070016A (ja) * 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041449A1 (fr) * 2007-09-25 2009-04-02 Kaneka Corporation Agent anti-obésité
GB2494475A (en) * 2011-09-12 2013-03-13 Works With Water Nutraceuticals Ltd A nutraceutical supplement and method of making
JP2013111064A (ja) * 2011-11-30 2013-06-10 Q P Corp 容器入り大根おろし含有液状調味料
JPWO2013132670A1 (ja) * 2012-03-05 2015-07-30 テルモ株式会社 半固形化栄養剤
WO2014188861A1 (fr) * 2013-05-20 2014-11-27 ユーハ味覚糖株式会社 Composition de type gel présentant une teneur élevée en ubiquinol
JP2014226050A (ja) * 2013-05-20 2014-12-08 ユーハ味覚糖株式会社 還元型コエンザイムｑ１０含有グミキャンディの製造方法および該製造方法を用いて得られるグミキャンディ
US9757332B2 (en) 2013-05-20 2017-09-12 Uha Mikakuto Co., Ltd. Gel-like composition having high ubiquinol content
JP2015029452A (ja) * 2013-08-01 2015-02-16 江崎グリコ株式会社 冷凍ゼリー
JP2015104342A (ja) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 ユビキノール高含有ゲル状組成物
JP2015105243A (ja) * 2013-11-29 2015-06-08 ユーハ味覚糖株式会社 ユビキノール含有液状組成物
JP2015209398A (ja) * 2014-04-25 2015-11-24 ユーハ味覚糖株式会社 高吸収型ユビキノール製剤

Also Published As

Publication number Publication date
JPWO2008035757A1 (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2008035757A1 (fr) Aliment de type gelée contenant de l'ubiquinol
JP5147239B2 (ja) コエンザイムｑ１０含有乳化組成物
JP4842824B2 (ja) コエンザイムｑ１０含有組成物
WO2007037249A1 (fr) Composition contenant un cello-oligosaccharide
WO2014175119A1 (fr) Agent ou procede pour le traitement et/ou la prevention de fonctionnalite de depense energétique accelerée et/ou de depense energetique reduite
WO2006112283A1 (fr) Agent anti-fatigue
JPWO2003077895A1 (ja) 糖尿病用組成物
JP5705898B2 (ja) 肝機能改善剤
KR20140021988A (ko) 금속 이온 나노클러스터
WO2005111224A2 (fr) Nouvelle forme hydrosoluble de la coenzyme q10 sous la forme d'un complexe d'inclusion avec de la beta-cyclodextrine, son procede de preparation et ses utilisations
BR112017005611B1 (pt) Agente de suprimento de energia, composição sacarídica, produto de alimento ou de bebida, agente para uso no tratamento e prevenção de uma doença ou um sintoma, e, uso de uma composição sacarídica
JP2009137916A (ja) 肥満改善用組成物
JP2022062711A (ja) 抗酸化性組成物
CN115279209A (zh) 辅酶q产生促进剂和辅酶q产生促进方法
WO2007080787A1 (fr) Compositions hydrosolubles contenant une coenzyme q10
JP5103374B2 (ja) 心機能不良改善剤または心機能維持剤
JPWO2004080469A1 (ja) 低血糖症状回復用補助食品
JP6456032B2 (ja) Ｓｉｒｔ１活性化剤および当該Ｓｉｒｔ１活性化剤の利用
JP6194192B2 (ja) アディポネクチン産生促進剤
JP7090864B2 (ja) 組成物
JP2020019737A (ja) ロイシン血中濃度上昇促進剤及びその用途
JP2013192514A (ja) 牡蠣エキスの製造方法
JP2012206964A (ja) ＰＰＡＲ−α活性調節剤
JP2009051751A (ja) 筋肉細胞糖輸送促進作用組成物
JP2004292355A (ja) 抗ストレス剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07807700

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008535395

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07807700

Country of ref document: EP

Kind code of ref document: A1